CompletedNCT02477670

Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia

This study evaluated the safety and effectiveness of AVP-786 for people with schizophrenia.

Medication studyAges 18–60United States

The study in practice

Understand this study

This study evaluated the safety and effectiveness of AVP-786 for people with schizophrenia.

This study was for people with schizophrenia. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.

Listed locations: Cerritos, United States · Garden Grove, United States and 15 more locationsSee all locations and recruitment
Activities: Medication described in the protocol · Placebo comparator
Compensation: Payment and expense reimbursement have not been verified.

Study clarity

Study start dateStarted: September 1, 2015

Recruitment status: Completed
Enrollment listed in the registry: 145
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Sponsor type: Pharmaceutical company
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 2
Locations: United States
Age range: From 18 Years to 60 Years
Official registry ID: NCT02477670
Official title: Show the full official title
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Sequential Parallel Comparison Design (SPCD) Study to Assess the Efficacy, Safety and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) as an Adjunctive Treatment for Patients With Residual Schizophrenia

Completed

Cerritos · Garden Grove · National City

14 more locations

FAQ

What did researchers investigate?

This study evaluated the safety and effectiveness of AVP-786 for people with schizophrenia.

Who is behind this study?

The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including AVP-786 and Placebo.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.